Spyre Q4 2023 net loss $63.2M; cash $339.6M; pipeline on track with SPY001 FIH H1 2024

Spyre Therapeutics, Inc.

2023-FY EPS reported -$49.12 revenue$886,000

Net loss $63.2M in Q4 2023 vs $18.8M in Q4 2022; cash $339.6M as of Dec 31, 2023.
Raised $180M gross from private placement; cash runway into H2 2026.
SPY001 anti-α4β7 shows 22-day half-life (3x vedolizumab); FIH studies expected H1 2024 with interim data year-end.
SPY002 anti-TL1A candidates nominated; preclinical half-life 24 days (2-3x clinical-stage); FIH in H2 2024.
Appointed CEO Cameron Turtle and board member Mark McKenna; name changed to Spyre Therapeutics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Spyre Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001636282-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.